ClinicalTrials.gg
CompletedNCT00262548Updated Aug 28, 2007

C-Reactive Protein (CRP) in Obese Diabetic Women

A Phase 4 interventional study of Rosuvastatin; improvement of lipid profile in Diabetes Mellitus, Type 2, sponsored by AstraZeneca. Completed at 1 site in Mexico. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2007-08-28.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.

Planned enrollment
161st of 280
100 · median 155
Started
2005
with 19 others
Phase 4
28 of 345
none open now
Registered
33rd of 345
by date

Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 161st largest by planned enrollment of the 280 interventional ones that give a count, is one of 20 that started in 2005, is one of 28 in phase 4, and was the 33rd registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 45 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Obesity
  • Menopause
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Menopausal
  • Diagnosed diabetes mellitus type 2
  • Obese ( [BMI] > 25 ≤ 30)

Exclusion criteria

Exclusion Criteria:

  • Fasting blood glucose ≥ 200 mg/dl
  • CRP \< 2 mg/L and > 10 mg/L
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
100 participants (estimated)

Interventions

  • DrugRosuvastatin; improvement of lipid profile
06

What researchers measure

Primary outcomes

  1. Patients will be receiving rosuvastatin/placebo for 6 months

  2. They will have baseline laboratory parameters taken such as glycemia

  3. HbA1c (glycosylated hemoglobin), low-density lipoprotein cholesterol (LDL-C), computed tomography (CT), high-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), and retaken every 3 months

  4. Every month, patients will be evaluated at the clinic

  5. All participants will receive an intervention on diet and physical activity counseling, which will be carefully monitored.

Secondary outcomes

  1. Other variables will be: proinflammatory cytokines - tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6), IL-12, Th2/Th3 cytokines -IL-4, IL-10 and transforming growth factor beta (TGF-beta)

07

Study locations

1 site
  • Research site
    Cuernavaca, Morelos, Mexico
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 28, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00262548
Lead sponsor
AstraZeneca
Collaborators
Mexican National Institute of Public Health
First posted
Dec 7, 2005
Start date
Oct 2005
Last update
Aug 28, 2007

Study contacts

Astra Zeneca Mexico Medical Director, MD
study director · AstraZeneca
Simón Barquera Cervera, MD
principal investigator · Mexican National Institute of Public Health
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion